Stocks to Watch: Great Ajax, Akumin, BioMarin Pharmaceutical

Dow Jones
2023/10/21

By Ben Glickman

 

Great Ajax Corp. said it wouldn't be acquired by Ellington Financial after the two real-estate investment trusts agreed to terminate a previously announced combination. Ellington will pay Great Ajax $5 million in cash and acquire 1.67 million shares of common stock for $6.60 a share in connection with the canceled deal. Shares of Great Ajax sink 17% to $5.29 after-hours.

Akumin said it had reached a deal with private-equity firm Stonepeak to go private, under which Stonepeak would convert its $470 million note to Akumin shares and invest $130 million in the company. The companies said shareholders of Akumin would receive $25 million in cash and some contingent value rights. Shares rise 58% to 23 cents after-hours.

BioMarin Pharmaceutical received approval from the Food and Drug Administration for its Voxzogo treatment in all pediatric age groups. The treatment, which was previously indicated for patients five or older in the U.S., addresses achondroplasia, a growth condition.

 

Write to Ben Glickman at ben.glickman@wsj.com

 

(END) Dow Jones Newswires

October 20, 2023 19:19 ET (23:19 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10